Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

The startup is expanding its services less than one year after it started offering compounded GLP-1 weight loss drugs.

Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...

Kwame Raoul is among several state AGs raising the alarm following complaints about online teleheath company Hims & Hers ...

Hims’s acquisition of Trybe Labs will put it in competition with health industry juggernauts such as Labcorp and Quest ...

What Hims & Hers stock could be witnessing now is a short-squeeze. As its stock began rising sharply, short-sellers move to get out. So over the past week, we’ve seen shares surge 60%. In midday ...

The big game didn't live up to the big billing, but there was plenty to take in during commercial breaks and halftime.

The Super Bowl aired a Hims & Hers commercial that is receiving backlash for its non-FDA approved weight loss drug. This drug ...

Many Americans have turned to Hims & Hers and other telehealth companies for copies of weight-loss drugs after struggling to ...

Investors could be overestimating the contribution of Hims & Hers' compounded GLP-1 medications to its top line. Read why I ...

Hims & Hers Health's (NYSE: HIMS) share price has surged recently, climbing above $60 and creating new 52-week and all-time ...